Hallervorden-Spatz Disease Drugs Market Size

Hallervorden-Spatz Disease Drugs Market size is expected to expand at significant growth rate during the forecast period i.e., between 2024-2036.  Hallervorden-Spatz disease or HSD, also known as, neurodegeneration with brain iron accumulation (NBIA), and pantothenate kinase-associated neurodegeneration (PKAN), is a genetic neurological disorder. The growth of the market can be attributed to the severity of the symptoms of HSD, which can lead to paralysis, coma, and even death if not treated timely. It is a rare condition, usually diagnosed in early childhood, but late onset can even delay diagnosis to adulthood. The incidence of HSD is estimated to be 2 to 5 per million individuals worldwide, as of 2020. There is no specific cure for HSD, and the medication is required lifelong. This is estimated to boost the market growth. In addition to this, the increasing investment in the R&D activities in the medical field, along with rising healthcare expenditure globally, is estimated to boost the hallervorden-spatz disease drugs market growth.